German Court's Injunction In Edward's Spenser Patent Litigation Goes Into Effect
Edwards Lifesciences has reported that the injunction against sales of Medtronic's transcatheter heart valves in Germany, issued in a July 12 court ruling, went into effect on Aug 26. The District Court of Mannheim ruled last month that Medtronic is infringing Edwards' Spenser patent for transcatheter heart valve technology and issued an injunction prohibiting the sale of CoreValve and CoreValve Evolut systems in Germany, and ordered a recall of these products. Edwards has now provided the bond required to initiate the injunction.
Edwards is providing for exceptions to the injunction to ensure German physicians continue to have access to therapy in instances where the Edwards Sapien XT valve is not indicated, subject to Medtronic's cooperation. Edwards will not seek compensation for the valves used in these compassionate cases in Germany. The patent that was the subject of this court ruling, the Spenser patent EP 2 055 266 B1, is in effect until 2022. Medtronic is appealing this ruling, as well as contesting the validity of the Spenser patent at the European Patent Office.